Select Region or Location
Americas
  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • Other Americas
Europe
  • Austria
  • Belgium
  • Bulgaria
  • Croatia/Hrvatska
  • Cyprus
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovak Republic
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Kingdom
  • Other Europe
Asia Pacific
  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Korea, Republic of
  • Malaysia
  • New Zealand
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Other Asia Pacific
Africa And Middle East
  • Egypt
  • Israel
  • Other Africa And Middle East
USD
Home Cart Sign in  
Chemical Structure| 1610414-00-0 Chemical Structure| 1610414-00-0

Structure of EC1167
CAS No.: 1610414-00-0

Chemical Structure| 1610414-00-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only! Not for Human Use. We Do Not Sell to Patients.

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]}{[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}
    {[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 1610414-00-0 ]

CAS No. :1610414-00-0
Formula : C33H45N7O17S
M.W : 843.81
SMILES Code : SC[C@@H](C(O)=O)NC([C@H](CC(O)=O)NC([C@H](CC(O)=O)NC(CC1=CC=C(CNC(NCCCC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)C=C1)=O)=O)=O
English Name :(9S,13S)-1-(4-(2-(((S)-3-Carboxy-1-(((S)-3-carboxy-1-(((R)-1-carboxy-2-mercaptoethyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)amino)-2-oxoethyl)phenyl)-3,11-dioxo-2,4,10,12-tetraazapentadecane-9,13,15-tricarboxylic acid
MDL No. :MFCD32201134

Safety of [ 1610414-00-0 ]

Application In Synthesis of [ 1610414-00-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1610414-00-0 ]

[ 1610414-00-0 ] Synthesis Path-Downstream   1~3

  • 1
  • [ 71420-92-3 ]
  • [ 1610414-00-0 ]
YieldReaction ConditionsOperation in experiment
Multi-step reaction with 3 steps 1.1: trifluoroacetic acid; triisopropylsilane / 0.5 h / 20 °C 2.1: N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 0.5 h / 20 °C / Cooling with ice; Inert atmosphere 3.1: piperidine / N,N-dimethyl-formamide 3.2: 1 h / Inert atmosphere
Multi-step reaction with 3 steps 1.1: trifluoroacetic acid; triisopropylsilane / methanol / 0.5 h / 20 °C 2.1: N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 0.5 h / 20 °C / Inert atmosphere 2.2: 20 °C / Cooling with ice; Inert atmosphere 3.1: piperidine / N,N-dimethyl-formamide; isopropyl alcohol / 20 °C / Inert atmosphere 3.2: 1 h / Inert atmosphere
Multi-step reaction with 3 steps 1.1: trifluoroacetic acid; triisopropylsilane / 0.5 h / 20 °C 2.1: N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 0.5 h / 20 °C / Inert atmosphere 2.2: 0.5 h / 20 °C / Inert atmosphere 3.1: N-ethyl-N,N-diisopropylamine; benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate / N,N-dimethyl-formamide / Inert atmosphere 3.2: Inert atmosphere
  • 2
  • [ 1610413-97-2 ]
  • [ CAS Unavailable ]
  • [ 1610414-00-0 ]
YieldReaction ConditionsOperation in experiment
43% Stage #1: C73H71ClN3O11PolS With piperidine In N,N-dimethyl-formamide; isopropyl alcohol at 20℃; Inert atmosphere; Stage #2: C34H54N4O10 With benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine for 1h; Inert atmosphere; Stage #3: With triisopropylsilane; trifluoroacetic acid; D,L-dithiothreitol In water 1.m Preparation of Compound 110 In a peptide synthesis vessel 109 (0.18 mmol) was loaded and washed with isopropyl alcohol (3xlOmL) followed by dimethylfonnamide (3xlOmL). Fmoc deprotection was carried out using 20% piperidine in dimethylfonnamide (3x10 mL). Kaiser tests were performed to assess reaction completion. To the vessel was then introduced 108 (1.2 equiv) in dimethylfonnamide, diisopropylethylamine (4.0 equiv), and PyBOP (2.0 equiv). Argon wasbubbled for 1 hr, the coupling solution was drained, and the resin was washed with dimethylfonnamide (3x10 mL) and isopropyl alcohol (3x10 mL). Kaiser tests were performed to assess reaction completion. Peptide was cleaved from the resin using a cleavage mixture consisting of dithiothreitol (114mg, 0.74 mmol) dissolved in a solution of trifluoroacetic acid (l9mL), H20 (0.5mL), triisopropylsilane (0.5mL). One-third of the cleavage mixture wasintroduced and argon was bubbled for 30 mm. The cleavage mixture was drained into a clean flask. The resin was bubbled 2 more times with more cleavage mixture, for 30 mm each, and drained into a clean flask. The drained cleavage mixture was then concentrated and purified by preparative HPLC in 0-30% acetonitrile/0.1% formic acid to yield 110 (66.9mg, 43%, ESI mlz = 844.57 [M+H]+).
Stage #1: C73H71ClN3O11PolS With piperidine In N,N-dimethyl-formamide Stage #2: C34H54N4O10 With benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide for 1h; Inert atmosphere; Stage #3: With triisopropylsilane; water; trifluoroacetic acid; D,L-dithiothreitol EXAMPLE. Peptide 110. EXAMPLE. Peptide 110. Table 2: Reagents for peptide 110 synthesis In a peptide synthesis vessel 109 (0.18 mmol) was loaded and washed with isopropyl alcohol (3xl0mL) followed by dimethylformamide (3xl0mL). Fmoc deprotection was carried out using 20% piperidine in dimethylformamide (3x10 mL). Kaiser tests were performed to assess reaction completion. To the vessel was then introduced 108 (1.2 equiv) in dimethylformamide, diisopropylethylamine (4.0 equiv), and PyBOP (2.0 equiv). Argon was bubbled for 1 hr, the coupling solution was drained, and the resin was washed with dimethylformamide (3x10 mL) and isopropyl alcohol (3x10 mL). Kaiser tests were performed to assess reaction completion. Peptide was cleaved from the resin using a cleavage mixture consisting of dithiothreitol (114mg, 0.74 mmol) dissolved in a solution of trifluoroacetic acid (19mL), H20 (0.5mL), triisopropylsilane (0.5mL). One-third of the cleavage mixture was introduced and argon was bubbled for 30 min. The cleavage mixture was drained into a clean flask. The resin was bubbled 2 more times with more cleavage mixture, for 30 min each, and drained into a clean flask. The drained cleavage mixture was then concentrated and purified by preparative HPLC in 0-30% acetonitrile/0.1% formic acid to yield 110 (66.9mg, 43%, 1H NMR consistent with structure of 110; ESI m/z = 844.57 [M+H]+).
  • 3
  • [ CAS Unavailable ]
  • [ 1610413-97-2 ]
  • [ 71989-14-5 ]
  • [ 1610414-00-0 ]
YieldReaction ConditionsOperation in experiment
43% Stage #1: H-cys(4-methoxytrityl)-2-chlorotrityl-resin; Fmoc-(tBu)Asp-OH With benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide Inert atmosphere; Stage #2: With piperidine In N,N-dimethyl-formamide Inert atmosphere; Stage #3: C34H54N4O10; Fmoc-(tBu)Asp-OH Further stages; 1.l; 1.m l. Preparation of Peptide Resin 109 In a peptide synthesis vessel H-Cys(4-methoxytrityl)-2-chlorotrityl-resin (0.87 mmol) was loaded and washed with isopropyl alcohol (3×10 mL) followed by dimethylformamide (3×10 mL). To the vessel was then introduced Fmoc-Asp(OtBu)-OH (2.0 equiv) in dimethylformamide, diisopropylethylamine (4.0 equiv), and PyBOP (2.0 equiv). Argon was bubbled for 1 hr, the coupling solution was drained, and the resin was washed with dimethylformamide (3×10 mL) and isopropyl alcohol (3×10 mL). Kaiser tests were performed to assess reaction completion. Fmoc deprotection was carried out using 20% piperidine in dimethylformamide (3×10 mL) before each amino acid coupling. The above sequence was repeated to complete 2 coupling steps. The resin was dried under argon for 30 min.In a peptide synthesis vessel 109 (0.18 mmol) was loaded and washed with isopropyl alcohol (3×10 mL) followed by dimethylformamide (3×10 mL). Fmoc deprotection was carried out using 20% piperidine in dimethylformamide (3×10 mL). Kaiser tests were performed to assess reaction completion. To the vessel was then introduced 108 (1.2 equiv) in dimethylformamide, diisopropylethylamine (4.0 equiv), and PyBOP (2.0 equiv). Argon was bubbled for 1 hr, the coupling solution was drained, and the resin was washed with dimethylformamide (3×10 mL) and isopropyl alcohol (3×10 mL). Kaiser tests were performed to assess reaction completion. Peptide was cleaved from the resin using a cleavage mixture consisting of dithiothreitol (114 mg, 0.74 mmol) dissolved in a solution of trifluoroacetic acid (19 mL), H2O (0.5 mL), triisopropylsilane (0.5 mL). One-third of the cleavage mixture was introduced and argon was bubbled for 30 min. The cleavage mixture was drained into a clean flask. The resin was bubbled 2 more times with more cleavage mixture, for 30 min each, and drained into a clean flask. The drained cleavage mixture was then concentrated and purified by preparative HPLC in 0-30% acetonitrile/0.1% formic acid to yield 110 (66.9 mg, 43%, ESI m/z=844.57 [M+H]+).
 

Historical Records

Categories